Journal article
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
Abstract
PURPOSE: The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with …
Authors
Berthold DR; Pond GR; Soban F; de Wit R; Eisenberger M; Tannock IF
Journal
Journal of Clinical Oncology, Vol. 26, No. 2, pp. 242–245
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 10, 2008
DOI
10.1200/jco.2007.12.4008
ISSN
0732-183X